INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,377 | +3.5% | 5,057 | +25.8% | 0.00% | – |
| Q2 2023 | $254,408 | +32.0% | 4,020 | +13.0% | 0.00% | – |
| Q1 2023 | $192,786 | +16.1% | 3,559 | +14.3% | 0.00% | – |
| Q4 2022 | $166,000 | +7.8% | 3,114 | -5.9% | 0.00% | – |
| Q3 2022 | $154,000 | -84.1% | 3,308 | -80.5% | 0.00% | -100.0% |
| Q2 2022 | $966,000 | -35.8% | 16,932 | -31.1% | 0.00% | -33.3% |
| Q1 2022 | $1,504,000 | +1734.1% | 24,585 | +1467.9% | 0.00% | – |
| Q4 2021 | $82,000 | +127.8% | 1,568 | +63.3% | 0.00% | – |
| Q3 2021 | $36,000 | -20.0% | 960 | -13.2% | 0.00% | – |
| Q2 2021 | $45,000 | +87.5% | 1,106 | +55.6% | 0.00% | – |
| Q1 2021 | $24,000 | +4.3% | 711 | -3.4% | 0.00% | – |
| Q4 2020 | $23,000 | +4.5% | 736 | -13.7% | 0.00% | – |
| Q3 2020 | $22,000 | -63.3% | 853 | -63.9% | 0.00% | – |
| Q2 2020 | $60,000 | +81.8% | 2,363 | +9.9% | 0.00% | – |
| Q1 2020 | $33,000 | – | 2,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |